THE FUTURE OF CARDIAC HEALTH:
New Imaging Technology Marks Major Shift in the Diagnosis and Treatment of Heart Disease
Editorial Feature | Nov 30, 2022 | Tech
In an otherwise bearish market, small-cap medical device stocks are offering investors a welcome respite from the bad news.
Specifically, while the overall market has declined throughout 2022, a handful of smaller companies developing new medical devices for cardiac patients have soared as much as 286%.1
- CVRx (CVRX), a Minneapolis company that manufactures a neuromodulation device for patients suffering from heart failure, saw its shares jump from $4.702 in April to $8.973 at the end of September – a gain of 90.8%4 when the S&P 500 was down -17% in the same period…
- Shares of Shockwave Medical (SWAV), which manufactures catheters for peripheral artery disease (PAD), soared 129%5 since late January…
- And Transmedics Group (TMDX), which makes devices to aid organ transplants, has seen its shares skyrocket as high as 286%6 in 2022.
That’s why investors are taking a close look at a company that has been developing a new diagnostic imaging platform that could lead to a breakthrough in the diagnosis and treatment of heart disease: Ventripoint Diagnostics Ltd. (OTCQB:VPTDF)(CSE:VPT)(OTCQB:VPTDF)(CSE:VPT).
Founded in 2005 by a team of expert scientists and entrepreneurs, the Toronto-based company aims to be a key player in the development of next-generation, point-of-care imaging solutions.
The potential in this sector is enormous. At the moment, cardiac diagnostics has remained reliant on MRI technologies developed more than 40 years ago7.
Yet all that may be about to change.
Cardiac Imaging Technology for the 21st Century
Ventripoint is pioneering a new type of cardiac imaging technology that could revolutionize the treatment of heart disease.
The company’s compact, portable Ventripoint Medical System (VMS) generates complete, highly accurate 3D models of the heart from standard 2D echocardiogram images.
These models provide doctors with accurate measurements of crucial diagnostic metrics, such as volume and ejection fraction calculations.
This means patients can bypass the expensive, difficult, often uncomfortable experience of having Magnetic Resonance Imaging (MRI) scans.
Instead of cardiac patients being thrust into a dark metal tube with clanging sounds for upwards of two hours, as is common with room-sized MRI machines in hospitals, the VMS technology utilizes the same small, hand-held ultrasound probe used for pregnant women.
Plus, Ventripoint Diagnostics Ltd. (OTCQB:VPTDF)(CSE:VPT)(OTCQB:VPTDF)(CSE:VPT) has partnered with one of the largest medical device companies in the world, GE Healthcare, to offer its potentially life-saving technology for use with the 1.2 million ultrasound units worldwide.
Of the collaboration, Kristin McLeod, Digital Manager, Cardiovascular Ultrasound, of GE Healthcare declared,
“We are excited to offer the opportunity to partner with third parties, to widen their market footprint while also potentially bringing more functionality for our users.”
Providing Critical Diagnostics When Cardiac Patients Need Them Most
One of the little-known secrets about the diagnosis and treatment of heart disease is just how difficult it is for cardiologists to get accurate information about the condition of their patients’ hearts.
The technology to get such information exists – but it’s hugely expensive and much scarcer than many people realize.
It’s estimated that tens of millions of heart patients worldwide are not getting the regular cardiac diagnostics they should because of the difficulty and expense of booking MRI scans.
In the U.S. alone, an estimated 20 million people suffer from heart disease with another 2.4 million, including 1.4 million small children, suffering from congenital heart defects (CHD).8
Guidelines from cardiology experts state that these patients should be checked with diagnostic imaging every three to six months.
Yet at present, the only way to get complete and accurate information is with the high-resolution 3D images produced by Magnetic Resonance Imaging or MRI scans – a time-consuming, laborious procedure that is usually fully booked.
The powerful, room-sized MRI machines cost between $3 to $5 million each and must be housed in hospital wings specially designed and built without any of the metal typically found in reinforced concrete.
The average cost of such a buildout… A whopping $20 million.
What’s more, many heart patients can’t have MRI scans done on them due to presence of metallic devices, such as stents or pacemakers, in their bodies.
Then consider that it’s estimated only 40 percent of heart patients will even submit to or are capable of getting the scans… and up to 25 percent of those are unable to finish the entire two-hour procedure, rendering the scans useless.
Worst of all, the economics of operating MRI machines means that openings for cardiac MRI screenings are rare because radiologists can scan up to ten cancer patients (15 to 20 minutes each) in the time it takes to scan one cardiac patient.
Equal In Accuracy To High-Resolution MRI Images, But At A Fraction of the Cost
This is why Ventripoint Diagnostics Ltd. (OTCQB:VPTDF)(CSE:VPT)(OTCQB:VPTDF)(CSE:VPT) could revolutionize the practice of cardiology – and potentially be a game-changer for millions of heart patients.
The Ventripoint technology is a relatively inexpensive (around $50,000) “add-on” device that works with most ultrasound scanners.
Yet with its proprietary and revolutionary Artificial Intelligence (AI) technology, it can generate accurate 3D models of the heart from ordinary ultrasound scans — and provide cardiologists with most of the crucial information they get from MRI machines.
This means that doctors can perform routine cardiac diagnostics in their own offices rather than having to wait months for an opening at a hospital’s MRI unit.
Endorsed by Experts Worldwide
Cardiologists and imaging experts worldwide can’t say enough about what Ventripoint could do for heart patients:
Richard Krasuski, MD, Director of Adult Congenital Heart Disease Services at the Cleveland Clinic’s Sydell and Arnold Miller Family Heart and Vascular Institute, says…
“The Ventripoint Medical System™ will enable us to better image the hearts of patients at risk for pulmonary hypertension and is a wonderful alternative to MRI. We currently can’t do an MRI in the majority of these patients given technical issues, the prohibitive expense and the inability to get payers to approve the procedure.”
Shelby Kutty, MD, Assistant Professor of Pediatrics and Radiology at the University of Nebraska Medical Center, says…
“We are pleased to be the first site in the US to be working with a research version of the Ventripoint Medical System (VMS). As the primary investigator of a multi-center trial to validate the systemic right ventricle database, I am enthusiastic about the advantages and accuracy of the VMS for patients with congenital heart disease.”
And Willem Helbing MD, Head of Pediatric Cardiology at Erasmus Sophia Children’s Hospital in Rotterdam, Netherlands, adds…
“The Ventripoint system combines the best of both worlds: the ease and availability of 2D echo and the intrinsic 3D information of the MRI acquired shapes of the right ventricle in the database. We anticipate a reduction of the need for (expensive) cardiac Magnetic Resonance Imaging (MRI) for the purpose of assessment of right ventricle volumes.”
And for investors, this brand-new technology could represent a rare opportunity to enhance their portfolio while also helping advance the treatment of heart disease.
No Competition in a Rapidly Growing Global Market
The best thing for investors about Ventripoint Diagnostics Ltd. (OTCQB:VPTDF)(CSE:VPT)(OTCQB:VPTDF)(CSE:VPT) is that it has pioneered a brand-new type of imaging system – and therefore has no direct competitors.
Big medical device conglomerates have tried for years to develop 3D ultrasound scanners to compete with MRI machines but have yet to succeed.
There are technical reasons why this is so, but the simple explanation is that a heart moves too quickly to be captured in a 3D holographic image. For this reason, doctors have had no choice but to rely on the only other existing imaging technology, MRI machines.
That is, until now.
In the U.S. alone, an estimated 20 million people over age 20 have coronary artery disease (CAD), and each year about 805,000 people are struck down by a heart attack.
Plus, another 2.4 million suffer from congenital heart defects, such as heart valve defects, that should be checked regularly.
Ventripoint estimates that to serve the needs of patients in the U.S., Canada, and Europe at least 50,000 of its VMS units would be needed.
At approximately $50,000 cost per unit, that represents potential future revenues of some $2.5 billion.
But that’s just based on current figures. Allied Market Research forecasts the global cardiac diagnostics segment to grow at a CAGR of 8.3% through 20309.
And right now, Ventripoint’s last handful of press releases indicate they have their eyes on this $6.8 million marketplace, that’s expected to more than double to $15.4 million in the next 8 years10.
On May 9, Ventripoint announced the hiring of two new strategic sales account managers to assist in the expansion of sales and distribution of the VMS+ diagnostic tool into the US and European markets. Another press release hinted at a potential interest by echocardiologists in Latin America.
Soon after, the company released news of a collaboration with Duke University School of Medicine in a new study that analyzes single ventricle cardiac function in children. This marks the first study to validate the VMS+3.0 in children with functional single ventricles.
Should Ventripoint’s novel technology prove accurate as this study progresses, it opens yet another application in great need of a flexible point-of-care solution.
Success Breeds Success
Ventripoint Diagnostics Ltd. (OTCQB:VPTDF)(CSE:VPT)(OTCQB:VPTDF)(CSE:VPT) management team seems uniquely qualified to capitalize on this opportunity.
Chairman of the Board Dr. George Adams is a scientist, serial entrepreneur and a financier who has been a director of 10 venture capital funds and 10 start-up companies. He has been helping develop the Ventripoint technology for more than a decade.
Adams’s previous positions include serving as CEO of Amorfix Life Sciences (TSX:AMF) from 2005-2010 and as chairman of Sernova Corp (TSXV:SVA) and president and CEO of the UT Innovations Foundation from 1999 until 2004. Prior to this, Adams held research and executive positions with Boston Scientific Inc, Pfizer Inc, Corvita Canada Inc., University of Ottawa and Canadian Red Cross’s Blood Transfusion Service.
Joining Dr. Adams is Randy AuCoin, currently the president and CEO of Exact Imaging, the world leader in high-frequency ultrasound for early detection of prostate cancer; Fiona Fitzgerald, the current National Zone Leader for Cytiva Life Science and accounts for all the commercial products in Canada; and Robert Hodgkinson, a financial expert with more than 40 years of experience in public and venture capital markets.
8 Reasons Why Ventripoint Diagnostics Ltd. (OTCQB:VPTDF)(CSE:VPT)(OTCQB:VPTDF)(CSE:VPT) Is Positioned For Growth
Reason #1: Growing Market. The cardiac diagnostics market is expanding despite a mediocre economy, projected to grow from $6.8 million to $15.4 million by 2030. 11
Reason #2: Breakthrough New Technology. Ventripoint Diagnostic’s new imaging technology is so new and exciting that some of the largest medical device companies in the world, such as GE Healthcare, have already made distribution deals with the company.
Reason #3: No Competition. Ventripoint’s 3D imaging technology is the only ultrasound 3D imaging solution for the heart currently on the market. With the average cost of a new MRI machine hovering around $5 million, which doesn’t include another $20 million for the hospital wing, cardiologists worldwide are desperate for Ventripoint Diagnostic’s low-cost, point-of-care solutions.
Reason #4: Endorsed by Experts Worldwide. Leading cardiologists and experts at diagnostic imaging have endorsed Ventripoint’s technology, saying that “Ventripoint Medical System™ will enable us to better image the hearts of patients at risk for pulmonary hypertension and is a wonderful alternative to MRI.”
Reason #5: Immediate Customers. Ventripoint’s imaging system can be used with most existing ultrasound devices, giving the company access to millions of customers almost immediately.
Reason #6: Dream Team. The team behind Ventripoint Diagnostics is impressive, with serial entrepreneur and Chairman of the Board Dr. George Adams having a proven track record with 10 startup companies and as a director of 10 venture capital funds
Reason #7: Huge Opportunity for Investors. Despite the enormous global market and potential for this technology, Ventripoint has just begun shipping its 3D imaging devices. As a result, it’s still possible to pick up shares of the company for less than $1 per share.
Reason #8: Making a Difference. Investors invest to make money. But it’s not very often that you can potentially make money while also contributing to a significant medical advance.
It appears there is nothing but upside for the rapidly growing company that still trades at a price well below its peers. But it may not for long. As more news is generated and word gets out, expect investors to discover this next-generation diagnostics solution.
Ask your broker about Ventripoint Diagnostics Ltd. (OTCQB:VPTDF)(CSE:VPT)(OTCQB:VPTDF)(CSE:VPT) today. And don’t forget to always perform your own due diligence research before investing in any stock.
1TMDX rose from $14.42 per share at the close on January 27, 2022, to a high of $55.75 per share at the close on September 12, 2022. See https://finance.yahoo.com/quote/TMDX/history?p=TMDX. Online calculator makes that a gain of 286%. https://percentcalc.com/
2 Closing price of $4.70 per share on April 18, 2022, per Yahoo! Finance: https://finance.yahoo.com/quote/CVRX/history?p=CVRX
3 Closing price of $8.97 on September 29, 2022, per Yahoo: https://finance.yahoo.com/quote/CVRX/history?p=CVRX
4 https://percentcalc.com/
5 SWAV rose from a closing price of $127.96 per share on January 27, 2022, to $293.49 at the close on September 19, 2022, a gain of 129% per https://percentcalc.com/
6 TMDX rose from $14.42 per share at the close on January 27, 2022, to a high of $55.75 per share at the close on September 12, 2022. See https://finance.yahoo.com/quote/TMDX/history?p=TMDX. Online calculator makes that a gain of 286%. https://percentcalc.com/
7 https://www.aps.org/publications/apsnews/200607/history.cfm
8 https://www.cdc.gov/ncbddd/heartdefects/data.html
9 https://www.alliedmarketresearch.com/cardiovascular-diagnostic-testing-market-A14287
10 https://www.alliedmarketresearch.com/cardiovascular-diagnostic-testing-market-A14287
11 https://www.alliedmarketresearch.com/cardiovascular-diagnostic-testing-market-A14287
IMPORTANT NOTICE AND DISCLAIMER
This article is a paid advertisement. Think Ink Marketing and its owners, managers, employees, and assigns (collectively “the Publisher”) is often paid by profiled companies or third parties to organize marketing campaigns, which include the creation and dissemination of these types of communications. In this case, in an effort to enhance public awareness of Ventripoint Diagnostics Ltd. (“VPTDF”) and its securities, VPTDF has provided the Publisher with a budget of approximately $10,000.00 USD to cover the costs associated with creating and distribution of this communication. The Publisher may retain any excess sums after expenses as its compensation. This compensation should be viewed as a major conflict with our ability to be unbiased. Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to hurt share prices. Frequently companies profiled in our articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in volume and share price may likely occur. This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security. Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position. The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser. This communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results. This communication is based on information generally available to the public and on interviews with company management, and does not (to the Publisher’s knowledge, as confirmed by VPTDF) contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher cannot guarantee the accuracy or completeness of the information.
SHARE OWNERSHIP.
The Publisher does not own any shares of any profiled company VPTDF and has no information concerning share ownership by others of in the profiled company VPTDF. The Publisher cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
FORWARD LOOKING STATEMENTS.
This publication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. The Publisher notes that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect the companies’ actual results of operations. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to VPTDF industry; (b) market opportunity; (c) VPTDF business plans and strategies; (d) services that VPTDF intends to offer; (e) VPTDF milestone projections and targets; (f) VPTDF expectations regarding receipt of approval for regulatory applications; (g) VPTDF intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) VPTDF expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute VPTDF business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) VPTDF ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) VPTDF ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) VPTDF ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of VPTDF to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) VPTDF operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact VPTDF business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing VPTDF business operations (e) VPTDF may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
INDEMNIFICATION/RELEASE OF LIABILITY.
By reading this communication, you acknowledge that you have read and understand this disclaimer, and further that to the greatest extent permitted under law, you release the Publisher, its affiliates, assigns and successors from any and all liability, damages, and injury from this communication. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
INTELLECTUAL PROPERTY.
Think Ink Marketing is the Publisher’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Publisher is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks.
IMPORTANT NOTICE AND DISCLAIMER
This website is owned and hosted by Market Tactic Media Ltd. Articles appearing on this website should be considered paid advertisements. Market Tactic Media Ltd. and its owners, managers, employees, and assigns (collectively “the Website Host”) is often paid by marketing companies to host websites on which articles profiling public companies are published. The Website Host has not been compensated by any of the profiled companies. The Website Host’s compensation for articles appearing on this website is as follows:
- The Website Host has been paid approximately $500 per week while the advertisement campaign is active by Think Ink Marketing as compensation to host the article profiling Ventripoint Diagnostics Ltd..
SHARE OWNERSHIP
The Website Host does not own any shares of any profiled Ventripoint Diagnostics Ltd. and has no information concerning share ownership by others of any profiled companies and The Website Host cautions readers to beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you read the articles on this website and this has the potential to hurt share prices. Frequently companies profiled in such articles experience a large increase in volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases.
NO SECURITIES OFFERED
The articles on this website are not, and should not be construed to be, offers to sell or solicitations of an offer to buy any security. Neither the articles on this website nor the Website Host purport to provide a complete analysis of any Ventripoint Diagnostics Ltd. or its financial position. The Website Host is not, and does not purport to be, a broker-dealer or registered investment adviser. The articles on this website are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the Ventripoint Diagnostics Ltd.. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the profiled Ventripoint Diagnostics Ltd.’s SEC and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk.
INDEMNIFICATION/RELEASE OF LIABILITY
By reading articles on this website, you acknowledge that you have read and understood this disclaimer, and further that to the greatest extent permitted under law, you release the Website Host, its affiliates, assigns and successors from any and all liability, damages, and injury from articles appearing on this website. You further warrant that you are solely responsible for any financial outcome that may come from your investment decisions.
LINKS TO THIRD PARTY WEBSITES
This website enables users to link to external websites not under the control of The Website Host. The Website Host has no control over the nature, content, and availability of those sites. The inclusion of any links is not intended as, and should not be construed as, a recommendation or endorsement of the content or views expressed on such external websites. The Website Host expressly disclaims any representation concerning the quality, safety, suitability, or reliability of any external websites and the content and materials contained in them. It is important for users to take necessary precautions, especially to ensure appropriate safety.
INTELLECTUAL PROPERTY
The Market Tactic is the Website Host’s trademark. All other trademarks used in this communication are the property of their respective trademark holders. The Website Host is not affiliated, connected, or associated with, and is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Website Host to any rights in any third-party trademarks.
FORWARD LOOKING INFORMATION
This document contains forward-looking information and forward-looking statements, within the meaning of applicable Canadian securities legislation, (collectively, “forward-looking statements”), which reflect expectations regarding Ventripoint Diagnostics Ltd. future growth, future business plans and opportunities, expected activities, and other statements about future events, results or performance. Wherever possible, words such as “predicts”, “projects”, “targets”, “plans”, “expects”, “does not expect”, “budget”, “scheduled”, “estimates”, “forecasts”, “anticipate” or “does not anticipate”, “believe”, “intend” and similar expressions or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved, or the negative or grammatical variation thereof or other variations thereof, or comparable terminology have been used to identify forward-looking statements. These forward-looking statements include, among other things, statements relating to: (a) revenue generating potential with respect to Ventripoint Diagnostics Ltd. industry; (b) market opportunity; (c) Ventripoint Diagnostics Ltd. business plans and strategies; (d) services that Ventripoint Diagnostics Ltd. intends to offer; (e) Ventripoint Diagnostics Ltd. milestone projections and targets; (f) Ventripoint Diagnostics Ltd. expectations regarding receipt of approval for regulatory applications; (g) Ventripoint Diagnostics Ltd. intentions to expand into other jurisdictions including the timeline expectations relating to those expansion plans; and (h) Ventripoint Diagnostics Ltd. expectations with regarding its ability to deliver shareholder value. Forward-looking statements are not a guarantee of future performance and are based upon a number of estimates and assumptions of management in light of management’s experience and perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances, as of the date of this document including, without limitation, assumptions about: (a) the ability to raise any necessary additional capital on reasonable terms to execute Ventripoint Diagnostics Ltd. business plan; (b) that general business and economic conditions will not change in a material adverse manner; (c) Ventripoint Diagnostics Ltd. ability to procure equipment and operating supplies in sufficient quantities and on a timely basis; (d) Ventripoint Diagnostics Ltd. ability to enter into contractual arrangements; (e) the accuracy of budgeted costs and expenditures; (f) Ventripoint Diagnostics Ltd. ability to attract and retain skilled personnel; (g) political and regulatory stability; (h) the receipt of governmental, regulatory and third-party approvals, licenses and permits on favorable terms; (i) changes in applicable legislation; (j) stability in financial and capital markets; and (k) expectations regarding the level of disruption as a result of COVID-19. Such forward-looking information involves a variety of known and unknown risks, uncertainties and other factors which may cause the actual plans, intentions, activities, results, performance or achievements of Ventripoint Diagnostics Ltd. to be materially different from any future plans, intentions, activities, results, performance or achievements expressed or implied by such forward-looking statements. Such risks include, without limitation: (a) Ventripoint Diagnostics Ltd. operations could be adversely affected by possible future government legislation, policies and controls or by changes in applicable laws and regulations; (b) public health crises such as the COVID-19 pandemic may adversely impact Ventripoint Diagnostics Ltd. business; (c) the volatility of global capital markets; (d) political instability and changes to the regulations governing Ventripoint Diagnostics Ltd. business operations (e) Ventripoint Diagnostics Ltd. may be unable to implement its growth strategy; and (f) increased competition. Except as required by law, the Website Host undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future event or otherwise.
HISTORICAL INFORMATION
Any graphs, tables or other information demonstrating the historical performance or current or historical attributes of Ventripoint Diagnostics Ltd. or any other entity contained in this document are intended only to illustrate historical performance or current or historical attributes of Ventripoint Diagnostics Ltd. or such entities and are not necessarily indicative of future performance of Ventripoint Diagnostics Ltd. or such entities.
